These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26286909)

  • 41. Flecainide causing elevated capture thresholds on pacemaker implantation.
    Leow KC; Lim WY; Lee A; Rahman M; Tan R
    BMJ Case Rep; 2024 Mar; 17(3):. PubMed ID: 38514158
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Syncope in patients with atrial flutter during treatment with class Ic antiarrhythmic drugs.
    Kawabata M; Hirao K; Horikawa T; Suzuki K; Motokawa K; Suzuki F; Azegami K; Hiejima K
    J Electrocardiol; 2001 Jan; 34(1):65-72. PubMed ID: 11239374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical evaluation in therapy of patients with atrial fibrillation or flutter.
    Waldo AL
    Cardiol Clin; 1990 Aug; 8(3):479-90. PubMed ID: 2205386
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Flecainide-induced JT prolongation, T wave inversion and ventricular tachycardia during treatment for symptomatic atrial fibrillation.
    Said SA; Somer ST; Oude Luttikhuis HA
    Int J Cardiol; 1994 May; 44(3):285-7. PubMed ID: 8077075
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved Ventricular Function after TEE-guided Cardioversion of Atrial Arrhythmias in Patients after the Fontan Operation.
    Poterucha JT; Egbe AC; Johnson JN; Niaz T; Wackel PL; Cannon BC; Eidem BW; Cetta F
    Congenit Heart Dis; 2016 Dec; 11(6):578-583. PubMed ID: 27030521
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of a protocol to select patients of all ages for cardioversion from atrial fibrillation.
    Lawson-Matthew PJ; Ionescu A; McHugh P; Channer KS
    Age Ageing; 1997 Jul; 26(4):247-52. PubMed ID: 9271286
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation.
    Berns E; Rinkenberger RL; Jeang MK; Dougherty AH; Jenkins M; Naccarelli GV
    Am J Cardiol; 1987 Jun; 59(15):1337-41. PubMed ID: 3109229
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Electrotherapy of severe arrhythmias].
    Saborowski F
    Dtsch Med Wochenschr; 1973 Mar; 98(13):675-7. PubMed ID: 4121286
    [No Abstract]   [Full Text] [Related]  

  • 49. [Drug and electrical therapy of supraventricular tachyarrhythmias].
    Heisel A; Jung J; Schieffer H
    Z Kardiol; 2000; 89 Suppl 3():68-74. PubMed ID: 10810788
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The epidemiology and management of recent-onset atrial fibrillation and flutter presenting to the Emergency Department.
    Hamilton A; Clark D; Gray A; Cragg A; Grubb N;
    Eur J Emerg Med; 2015 Jun; 22(3):155-61. PubMed ID: 25203594
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and electrophysiological characteristics of patients having atrial flutter with 1:1 atrioventricular conduction.
    Kawabata M; Hirao K; Higuchi K; Sasaki T; Furukawa T; Okada H; Hachiya H; Isobe M
    Europace; 2008 Mar; 10(3):284-8. PubMed ID: 18258806
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardioversion of tachycardias by transesophageal atrial pacing.
    Montoyo JV; Angel J; Valle V; Gausí C
    Am J Cardiol; 1973 Jul; 32(1):85-90. PubMed ID: 4713115
    [No Abstract]   [Full Text] [Related]  

  • 53. [Can 1/1 atrial flutter be foreseen by class I anti-arrhythmics?].
    Brembilla-Perrot B; Terrier de la Chaise A; Jacquemin L; Beurrier D; Houplon P; Louis P; Danchin N
    Arch Mal Coeur Vaiss; 1997 Jul; 90(7):961-6. PubMed ID: 9339257
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The clinical application of cardioversion.
    Zipes DP
    Cardiovasc Clin; 1970; 2(2):239-60. PubMed ID: 4950415
    [No Abstract]   [Full Text] [Related]  

  • 55. Atrial flutter, atrial fibrillation, and other primary atrial tachycardias.
    Benditt DG; Benson DW; Dunnigan A; Gornick CC; Anderson RW
    Med Clin North Am; 1984 Jul; 68(4):895-918. PubMed ID: 6381928
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Failure of diltiazem to prevent 1:1 conduction of atrial flutter: a case report.
    Tiver KD; Martin DK; Quah J; Lahiri A; Ganesan AN
    J Med Case Rep; 2023 Jul; 17(1):319. PubMed ID: 37464369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differentiation of the electrophysiological effects on the atrial myocardium between the pure Na channel blocker, pilsicainide, and flecainide.
    Kanemoto M; Shimizu A; Yamagata T; Esato M; Ueyama T; Yoshiga Y; Kakugawa H; Kametani R; Inoue N; Sawa A; Matsuzaki M
    Cardiovasc Drugs Ther; 2004 Jul; 18(4):295-303. PubMed ID: 15367827
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Direct-current cardioversion of atrial tachyarrhythmias under oral flecainide therapy.
    Leclercq JF; Bizot J; Attuel P; Coumel P
    Am J Cardiol; 1997 Sep; 80(5):645-8. PubMed ID: 9295002
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of cardiac arrhythmias.
    Med Lett Drugs Ther; 1974 Dec; 16(25):101-8. PubMed ID: 4431383
    [No Abstract]   [Full Text] [Related]  

  • 60. Flecainide acetate for the treatment of atrial and ventricular arrhythmias.
    Apostolakis S; Oeff M; Tebbe U; Fabritz L; Breithardt G; Kirchhof P
    Expert Opin Pharmacother; 2013 Feb; 14(3):347-57. PubMed ID: 23294160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.